Abstract: Necrotizing enterocolitis (NEC) is a common gastrointestinal inflammatory necrosis affecting almost exclusively premature infants usually after oral nutrition has been started, for example, 10 day plus postpartum. Although the pathogenesis is incompletely understood, major risk factors include prematurity and incomplete bacterial colonization. Evidence has been shown that the premature infant because of rapid passage through the birth canal or because of delivery by cesarean section has an inadequate initial ingestion of maternal colonic and vaginal flora and therefore, an inadequate initial colonization with less diversity of bacteria phylla and fewer species of bacteria in the microbiota. As a result, they are more susceptible to environmental pathogens. In addition, prematures have immature intestinal defenses (glycocalyx, tight junctions, innate immune response, etc.) resulting in excessive inflammation in response to luminal stimuli. Recently, we reported that genes mediating the innate inflammatory immune response are developmentally expressed with an increase in toll-like receptors, signaling molecules and transgenic factors and decreased negative regulators of inflammation, which undoubtedly contribute to an excessive inflammatory response. Several clinical studies have suggested that the use of probiotics and ingestion of expressed maternal breast milk containing probiotics can help to stabilize colonization and to reduce the incidence and severity of NEC when given to premature infants at risk. Meta-analyses of multiple small studies strongly suggest a protective effect in the use of probiotics. A multicenter study in Taiwan suggests that Bifidobacteria infantis and Lactobacillus acidophilus in combination may prevent NEC. These meta-analyses suggest that these probiotics should be used in routine care of premature infants. Other clinicians, however, suggest caution, holding out for a single protocol multicenter trial before routine use can be suggested.
N ecrotizing enterocolitis (NEC) is a potentially devastating disease, characterized by severe intestinal inflammation and necrosis, which occurs primarily in preterm infants. Although it is the most common gastrointestinal emergency of neonates, advances in the prevention and management of this disorder, compared with global advances in neonatal care, in general, have been relatively limited. 1, 2 The risk of developing NEC is inversely related to gestational age and birth weight. However, a small percentage of cases occur in full-term infants, and may represent a distinct disease entity. 3 According to data in the United States and Canada, the mean prevalence of NEC in neonates between 500 and 1500 g at birth is approximately 7%. [4] [5] [6] [7] Neonates younger than 28 weeks gestation and of extremely low birth weight (<1000 g) are particularly susceptible. 8 The pathogenesis is poorly understood despite decades of research, and therefore, continued scientific investigation in this area has become a priority. 9, 10 An exaggerated inflammatory response of the immature intestine occurs during a complex interplay between bacterial colonization, initiation of enteral nutrition, and hypoxic-related intestinal injury. In a susceptible host, this process may contribute to the development of intestinal necrosis, and ultimately NEC. 9 Intestinal innate immune responses mature throughout gestational development, therefore prematurely born infants are required to interact with the extrauterine environment with ill-equipped intestinal immunity.
Abdominal distention, feeding intolerance, and bloody stools comprise the classic triad of signs and symptoms described in NEC. Regardless of gestational age, NEC often presents after 8 to 10 days of age. The initial signs and symptoms may be subtle and nonspecific, emphasizing the importance of meticulous monitoring once enteral feeds have been initiated. Ominous clinical progression includes intestinal perforation, peritonitis, and hemodynamic instability. Radiographic findings such as fixed, dilated small bowel loops, extraluminal air, paucity of intestinal gas, pneumatosis intestinalis, and portal venous gas, suggest severe disease. Although some neonates respond to aggressive medical management, others require acute surgical intervention as well. The effective management option depends upon the baseline clinical condition of the neonate and the extent and severity of disease at the time of diagnosis. There are a number of NEC-like syndromes described in the literature, which may occur in preterm or term infants. The relatively older preterm infant may develop a disorder of intestinal inflammation and necrosis, which seems clinically similar to NEC, typically during the first week of life. This may represent a unique pathogenesis, as comorbid conditions such as congential heart disease, intestinal anomalies and perinatal stress, and specific risk factors such as intrauterine illicit drug exposure, have been associated with these cases. 11, 12 Spontaneous intestinal perforation in preterm infants is likely an unrelated entity as the pathognomonic findings of intestinal inflammation and necrosis are very mild. 4, 13, 14 The mortality rate associated with NEC is approximately 20% to 30% in all neonates, with those requiring surgical intervention facing an increased risk. 15 Morbidity is due to the intestinal sequelae of the disease process, such as intestinal strictures, and surgical outcomes, such as short bowel syndrome after intestinal resection. In addition, the extension of the inflammatory effects systemically may result in extraintestinal morbidity, particularly chronic neurodevelopmental impairment. This is particularly true of extremely low birth weight infants. 16, 17 In addition to birth weight, the degree of neurodevelopmental impairment is also associated with the severity of NEC. Although infants with NEC requiring surgical intervention without associated late bacteremia had an increased risk of psychomotor developmental delay, odds ratio (OR) = 2.7 (range, 1.2 to 6.4), those with associated late bacteremia had a markedly increased risk of diparetic cerebral palsy, OR = 8.4 (range, 1.9 to 39), and microcephaly, OR = 9.3 (range, 2.2 to 40). Infants with medically managed NEC and late bacteremia were twice more likely to develop diparetic cerebral palsy than those with late bacteremia alone (6% vs. 3%). 18 Initiation of enteral nutrition is a prerequisite to the development of NEC. As a preventive strategy, several institutions have established prolonged parental nutrition protocols, which have lead to increased infectious risk and delayed hospital discharge. 19 Delays in enteral nutrition may promote atrophic changes of the intestine and therefore may prolong the process of enteral nutrition initiation and advancement later. The expense of neonatal care provided to infants with NEC in the United States is estimated to be $500 million and $1 billion annually. Hospitalizations are prolonged by 20 to 60 days on average compared with the length of stay for neonates without NEC. The most common chronic consequence of surgically managed NEC, short-bowel syndrome, incurs $1.5 million for 5 years of continued outpatient care per patient. 4, 20 ESTABLISHMENT OF INTESTINAL MICROBIOTA Before intestinal colonization, the newborn intestine is sterile. Several host and microbial factors affect the process of intestinal microbiota acquisition and ultimately the bacterial composition. 21 The critical process of bacterial colonization is altered by mode of delivery, antibiotic exposure, neonatal environment, and source of nutrition. Bacterial strains known to colonize the newborn intestine include beneficial strains such as Bifidobacterium and Lactobacillus, those which are potentially harmful, such as Escherichia coli and Bacteroides and opportunists, including Clostridia, Staphylococcus, and Pseudomonas aeruginosa. 22 Newborns delivered vaginally are colonized with beneficial bacterial strains earlier than those delivered by cesarean section. In addition, increased colonization of Klebsiella, Enterobacter, and Clostridia is associated with cesarean delivery. [23] [24] [25] Breast-fed infants are primarily colonized with Bifidobacterium, with minor populations of Lactobacillus and Streptococcus. In contrast, formula-fed infants are primarily colonized with Bacteroides and Bifidobacterium, with minor populations of Clostridia, Staphylococcus, and Escherichia coli. [25] [26] [27] The process of bacterial colonization is delayed in premature infants, which may be due to relative environmental sterility and antibiotic use (Fig. 1 ). In addition, the risk of colonization with pathogens is increased in this population compared with full-term infants. 28 A critical relationship exists between the various enteric bacterial populations and the underlying balance of this relationship is necessary for host health. An imbalance, or dysbiosis, is responsible for compromised host health and ultimately clinical disease expression. 29 The effects of pathogenic bacterial dominance include diarrhea, enteric infections, liver disease, carcinogenesis, and intestinal putrefaction. 30 In contrast, the effects of beneficial bacteria, which promote host health, may include inhibition of pathogenic bacterial growth, promotion of immune function, diminution intestinal gas production, and improvement of digestion and absorption.
When the process of weaning is complete, the established intestinal microbiota approaches that of an adult. 30 
HOST IMMATURITY OF THE PRETERM INFANT
The fetal immune system has evolved to avoid maternal rejection rather than to process potential pathogens. 31 Therefore, after delivery, significant alterations of the neonatal immune system occur to allow postnatal tolerance of the extrauterine environment. 32 The development of postnatal immune function, characterized by a shift from a Th2-predominant to Th1-predominant phenotype, has been shown to be strongly influenced by the intestinal microbiota. 33, 34 After the initial stages of postnatal colonization, intestinal immune responses adapt to the increased microbial stimulation. 35, 36 There are several functional characteristics of the mature intestine, which limit the ability of bacteria to enter the intestinal lumen and prevent bacterial adherence and translocation. In addition, the innate and adaptive immune responses to luminal bacteria are closely regulated in the mature intestine by negative feedback inhibition of toll-like receptor (TLR) activation. Negative inflammatory regulators, such as MyD88, IRAKM, ST2, and SOCS1, allow a controlled inflammatory response. 37 Relative intestinal immaturities of the preterm infant include abnormal peristalsis, unique adhesion site glycoconjugates, 38, 39 intestinal mucus composition, 40 increased intestinal permeability, secretory IgA levels, [41] [42] [43] lower gastric acidity, trefoil factor deficiency, [44] [45] [46] and alterations of defensins. 47, 48 An exaggerated inflammatory response to both commensal and pathogenic bacteria has been demonstrated in human immature enterocytes, compared with mature enterocytes. 49, 50 This may be due to aberrant inflammatory regulator expression in the immature intestine. Developmentally regulated changes result in decreased IkB expression and increased TLR4 expression in immature enterocytes, allowing a more robust inflammatory response. 49, 51, 52 In addition, the expression of several positive and negative regulators of intestinal inflammation was shown to be distinctly different between immature and mature human enterocytes. Immature human enterocytes and intestinal xenografts showed increased expression of TLR4, TLR2, MyD88, TRAF-6, and NFkB1 and decreased expression of SIGIRR, IRAK-M, A-20, and TOLLIP (Fig. 2) . This inflammatory regulator profile was further altered in NEC enterocytes. 53 The intestinal immaturity and unique environmental factors of the preterm infant may alter the interaction between colonizing bacteria and the developing enteric immune system, further compounding the risk of NEC.
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ROLE OF INTESTINAL MICROBIOTA IN NEC
Clinical trials demonstrating a reduction in the incidence of NEC in premature infants receiving probiotic supplementation emphasize the importance of commensal bacteria colonization in the early postnatal period. [54] [55] [56] The interaction of the immature intestine with the extrauterine microbial environment after delivery is a critical risk factor in the pathogenesis of NEC. The inability to induce a NEClike disease process in germ-free in vivo models supports the importance of luminal bacteria in the pathogenesis of this disease. NEC typically develops after 8 to 10 days of life, which parallels the timeline required for intestinal colonization by anaerobes. 57, 58 Using 16s rRNA sequencing, the fecal bacterial strain diversity is significantly decreased in preterm infants who develop NEC, compared with those who do not. 59 Molecular bacterial analysis of fecal samples of preterm infants have shown that atypical species and reduced diversity is associated with an increased risk of developing NEC. 59, 60 Decreased fecal microbial diversity of the gut microbiome is common to a variety of clinical conditions that may be related to dysbiosis, including NEC. 61 A rich intestinal microbial diversity protects against colonization with potential pathogens, and therefore the lack of this diversity, as seen in preterm infants, is considered an additional contributing factor to the pathogenesis of NEC.
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ROLE OF PROBIOTICS IN NEC
Given the scientific understanding of NEC pathogenesis and the abnormal colonization patterns of preterm infants, strategies to favorably alter the intestinal microbiota could offer an effective preventive approach against this devastating disease. Probiotic bacteria may promote a healthy intestinal microbial balance and enhance intestinal immune function, which would provide an element of protection against NEC in the neonate. The mechanisms by which probiotics protect against intestinal disease include optimizing microbial balance, competitive exclusion of pathogens, promotion of mucus secretion, production of bacteriocins, enhancement of barrier integrity, and maturation of intestinal immunity. 61 The mechanism of protection depends upon the specific probiotic strain and disease model used in investigation. 61 In clinical trials investigating probiotics as a preventive strategy for NEC, commensal strains known not to translocate or cause mucosal injury to the host are typically chosen. 62 Not all probiotic strains have the same immunologic effects, even between bacteria of the same species. 63, 64 However, selection of the optimal probiotic strain or combination regimen is critical in obtaining desired protective effects, and the mechanisms of probiotic reduction of NEC are not well understood. [63] [64] [65] At the time of our last published review of probiotic use in NEC in 2008, there were 5 clinical trials investigating the use of orally administered probiotics in the prevention of neonatal NEC. [66] [67] [68] [69] [70] These studies varied in size, enrollment criteria, probiotic strain, timing of intervention, probiotic dose, and specific outcome measures. Of the 3 studies, which showed a statistically significant reduction in the incidence of NEC, 66,68,70 2 were prospective, randomized, controlled trials. 66, 70 The first three studies, by Hoyos 68 included all newborns admitted to a neonatal intensive care unit in Colombia, regardless of size or gestational age. L. acidophilus and B. infantis administration decreased the incidence of NEC from 6.6% to 2.9%, compared with historical controls. The 2 subsequent studies in 2005, by Lin et al 70 in Taiwan and Bin-Nun et al 66 in Israel, enrolled only preterm infants <1500 g and investigated 2 different combination probiotic regimens using a prospective, randomized, control trial design. They showed a significant reduction in the incidence of NEC with combined L. acidophilus and B. infantis in the former, and combined B. infantis, Streptococcus thermophilus, and Bifidobacterium bifidus, in the latter.
Deshpande et al 71 published a systematic review of 11 randomized, controlled trials between 1997 and 2009, from the Cochrane Central register, which included 2176 neonates. Trials selected for this meta-analysis included any randomized controlled trail which investigated the use of an orally administered probiotic regimen, started within the first 10 days of life, continued for Z7 days in preterm very-lowbirth-weight neonates (<34 wk gestation and birth weight <1500 g) and included stage II-III (severe) NEC as an outcome measures, using Modified Bell staging criteria. 66, 67, 69, 70, [72] [73] [74] [75] [76] [77] [78] This meta-analysis included the 2 randomized controlled trails discussed in our 2008 review. The data from these trials reported an incidence of severe NEC as 6.56% in the control group compared with 2.37% of the probiotic group. A fixed-effects analysis estimated a decreased risk of severe NEC in neonates supplemented with probiotics [relative risk (RR): 0.35; 95% confidence interval (CI), 0.23-0.55; P<0.00001]. Heterogeneity between trials was minimal and the NNT to prevent 1 case of severe NEC was 25 (95% CI, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Data analysis of the 10 trials, which included culture-positive sepsis as an outcome measure, showed no significant difference between the 2 groups, however, significant trial design heterogeneity was noted.
66,67,69,70,72,73,75-78 Data from 9 trials showed a reduced risk of all cause mortality in the probiotic group compared with the control group (RR: 0.42; 95% CI, 0.29-0.62; P<0.00001), with no significant trial heterogeneity. 66, 67, 69, 70, 73, [75] [76] [77] [78] In addition, the risk of NEC-associated mortality was similar between groups (RR: 0.30; 95% CI, 0.08-1.081), with no significant trial heterogeneity. 66, 67, 69, 73, 76 The most recent Cochrane Collaboration Review, by AlFaleh et al, 56 was published in 2011. This analysis included randomized controlled trials, which enrolled infants <37 weeks gestation and/or <2500 g at birth, investigated an orally administered probiotic regimen and reported severe NEC (stage II-III) and positive blood or cerebral spinal fluid cultures after 5 days of age. 66, 67, 69, 70, [72] [73] [74] [75] [76] [77] [78] [79] [80] Two new trials completed since the Deshpande et al 71 review qualified for inclusion in the AlFaleh analysis. 79, 80 The 2011 Cochrane Review reported a significantly reduced incidence of severe NEC in the probiotic groups of 13 qualified studies, regardless of birth weight (RR: 0.35; 95% CI, 0.24-0.52; NNT 25) and similar findings in the neonates <1500 g at birth, from 12 of these studies (RR: 0.34; 95% CI, 0.23-0.50). 66, 67, 69, 70, 72, 73, [75] [76] [77] [78] [79] [80] Four of the 13 studies were considered superior, based on standard Cochrane Collaboration methods of determining methodological quality. 67, 70, 76, 79 The data from these trials showed a significant reduction in the incidence of NEC in the probiotic group compared with controls (RR:0.25; 95% CI, 0.13-0.49). Ten studies reported all-cause mortality, 66, 67, 69, 70, 73, [76] [77] [78] [79] 81 which showed a significantly reduced incidence in the probiotic group compared with controls (RR: 0.40; 95% CI, 0.27-0.60) and 5 studies reported NEC-associated mortality, 66, 67, 69, 76, 80 which also showed a significantly reduced incidence in the probiotic group (RR: 0.31; 95% CI, 0.10-0.94). Sepsis was reported in all 13 trials, and was not different between groups (RR: 0.90; 95% CI, 0.76-1.07). Although the data included extremely low birth weight infants, data specific to this subgroup could not be determined.
Since the publication of the 2011 Cochrane Review, an additional prospective, double-blind, randomized, controlled clinical trial was conducted by Braga et al 82 Preterm infants with a birth weight between 750 to 1499 g received either human milk supplemented with Bifidobacterium breve or Lactobacillus casei or human milk alone, initiated during the second day of life. The primary outcome was stage Z2 NEC by Bell modified criteria, which was noted in 3.6% of the control group and not noted in the probiotic group (P = 0.05). In addition, there were no significant differences in the incidence of sepsis or mortality between groups.
CONCERNS
Although data supports the efficacy of probiotics in the prevention of NEC, concerns regarding the safety of probiotic prophylaxis in neonates remain. Given the relative immune compromise and specific immaturities of intestinal function in preterm infants, probiotic translocation and subsequent sepsis is of concern. There was an increased risk of sepsis in neonates receiving orally administered probiotics in the randomized, controlled clinical trial by Lin et al, 76 especially in the most vulnerable neonates with birth weights <750 g. However, none of the positive blood cultures grew Lactobacillus or Bifidobacterium spp. Although several trials included infants <1000 g, the data is insufficient to allow analysis of this subpopulation alone. All trials included in the 2010 Deshpande et al 71 meta-analysis and 2011 Cochrane Review by AlFaleh et al 56 showed no cases of probiotic sepsis, however, this has been reported in neonates and immunocompromised hosts before these reviews. [83] [84] [85] [86] [87] In addition, given design variability of the trials showing efficacy of probiotics in NEC prevention, the optimal probiotic strain, duration of administration, and host selectivity remain unclear. Although data demonstrate strain-specific immunologic effects, a consistently decreased risk of NEC in trials using variable probiotic regimens suggests strain nonspecific protection. Whether intact, live bacteria are required for their immunoprotective effects in neonates remains unanswered. Data suggest that bacterial components or secreted bioactive factors may provide effective, novel preventive strategies without the risk of probiotic-associated morbidity, such as sepsis.
CONCLUSIONS
Despite advances in neonatal care and improved survival of premature infants, NEC continues to be devastating intestinal disorder, which afflicts this vulnerable population. Prematurity is the primary risk factor for NEC. Immaturity of the intestinal immune system, leading to exaggerated inflammatory responses, leaves the neonate ill equipped to tolerate the extrauterine microbial environment. The role of intestinal microbes in the pathogenesis of disease has been established and appropriate bacterial colonization can promote intestinal maturation and health. Therefore, postnatal acquisition of a beneficial microbiota balance and variety is critical to newborn health and administration of probiotics may provide an opportunity to modify the microbiota toward an advantageous balance. Several randomized, controlled clinical trials have shown a statistically significant reduction in the incidence of NEC in preterm infants with orally administered probiotics; however, consensus on the optimal strain, dose, timing of administration, and host characteristics remains unclear due to heterogeneity of trial design. A theoretical risk of probiotic-associated morbidity exists in the neonatal population, particularly given the immaturities of intestinal function and immune status. Despite this risk, probiotic-associated sepsis occurred very infrequently in the randomized, controlled clinical trials included in this review. Repeated studies using a single design protocol to demonstrate reproducibility, safety, and efficacy would significantly strengthen the existing data. Data stratification of the previous clinical trials may be helpful in guiding the most promising protocol for future pursuit. These studies should also be powered to allow sufficient data from the most vulnerable neonates, those <1000 g at birth. Further research to demonstrate the exact mechanisms by which specific probiotics protect against intestinal disorders is also still necessary, and will ultimately allow data-supported, disease-specific clinical application in the future.
